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Abstract
Homologous Replacement is used to modify specific gene sequences of chromosomal DNA in a process referred to as
‘‘Small Fragment Homologous Replacement’’, where DNA fragments replace genomic target resulting in specific sequence
changes. To optimize the efficiency of this process, we developed a reporter based assay system where the replacement
frequency is quantified by cytofluorimetric analysis following restoration of a stably integrated mutated eGFP gene in the
genome of SV-40 immortalized mouse embryonic fibroblasts (MEF-SV-40). To obtain the highest correction frequency with
this system, several parameters were considered: fragment synthesis and concentration, cell cycle phase and methylation
status of both fragment and recipient genome. In addition, different drugs were employed to test their ability to improve
technique efficiency. SFHR-mediated genomic modification resulted to be stably transmitted for several cell generations
and confirmed at transcript and genomic levels. Modification efficiency was estimated in a range of 0.01–0.5%, further
increasing when PARP-1 repair pathway was inhibited. In this study, for the first time SFHR efficiency issue was
systematically approached and in part addressed, therefore opening new potential therapeutic ex-vivo applications.
Citation: Luchetti A, Filareto A, Sanchez M, Ferraguti G, Lucarelli M, et al. (2012) Small Fragment Homologous Replacement: Evaluation of Factors Influencing
Modification Efficiency in an Eukaryotic Assay System. PLoS ONE 7(2): e30851. doi:10.1371/journal.pone.0030851
Editor: David T. Kirkpatrick, University of Minnesota, United States of America
Received July 13, 2011; Accepted December 26, 2011; Published February 16, 2012
Copyright:  2012 Luchetti et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by Fondazione Cenci Bolognetti and by Fondazione Roma. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: sangiuolo@med.uniroma2.it
. These authors contributed equally to this work.
Introduction
In situ modification by gene targeting approach allows the
recovery of a normal gene function [1], offering significant
advantages compared to gene augmentation. Mutated genetic
instructions are site-specifically modified in long-term and
genetically inheritable manner, maintaining their native sequence
context. By this way, targeted gene results modulated by the
endogenous regulatory machinery, thus maintaining physiologic
expression pattern. In mitotic cells, homologous recombination
(HR) is a basic mechanism to repair DNA damage and in
particular DNA double-strand breaks (DSBs). Two main issues
hamper easy gene targeting in vertebrate cells: the low frequency
of HR events, generally occurring once every 10
5–10
7 treated
cells, and the high rate of random (non-homologous) integrations,
that occur approximately once every 10
2–10
4 treated cells. Among
different gene targeting strategies currently employed in labora-
tory, Small Fragment Homologous Replacement (SFHR) uses
Small DNA Fragments (SDFs) to obtain homologous replacement
in recipient cells [2]. Once within cells, SDFs trigger the exchange
between their sequences and the genomic DNA [3] through a still
undefined mechanism [4]. It is likely that the fragment recognizes
and anneals to its homologous target, promoting the formation of
a D-loop structure. This hybrid structure could activate the
endogenous machinery involved in DNA repair and, by HR, allow
the SDF to be integrated into the genomic DNA [5]. SFHR was
successfully used to target genomic mutations with different
features, working in vitro and in vivo in both human and mouse
cells, demonstrating its ability to correct several disease-associated
genes [6], such as: Cftr [7–11] (Cystic Fibrosis), Dystrophin [12,13]
(Muscular Dystrophies), SMN [14,15] (Spinal Muscular Atrophy),
DNA-PKs [16] (SCID), HPRT [17] and b-globin [18] (b–
thalassemia). Importantly, the SFHR-mediated DNA modification
has been shown to properly target genomic DNA in both
differentiated and undifferentiated stem cells [18], resulting in
long-term correction through clonal expansion.
Among factors influencing targeting mechanism, changes in the
chromatin structure during cell cycle, as well as cell mechanisms
involved in genome structure maintenance, are key factors in
SFHR efficiency [19–21]. Moreover, epigenetic changes were
detected after in vitro gene targeting of stem cells [22]. Together
these evidences strongly suggest functional interconnections
between molecular mechanisms controlling chromatin structure,
cell cycle, DNA methylation, DNA repair and gene targeting.
To date, studies linking SFHR to epigenetic modifications or to
cell cycle are still missing. Even if the potential of SFHR is
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e30851promising, it is currently limited by low and variable frequency of
correction, ranging from 0.01% to 5% in vitro and about 0.1% in
vivo [2]. Furthermore the absence of a selectable marker makes
difficult to quantify and optimize the efficiency of SFHR-mediated
modifications. In this study we developed an in vitro reporter assay
system able to properly quantify the percentage of SFHR-modified
cells. A mutated non-fluorescent eGFP gene was stably integrated
within genomic DNA of immortalized murine embryonic
fibroblasts. Transfected SDFs were homologous to eGFP wild-
type sequence, allowing reporter fluorescence recovery. The aim
of this work was to evaluate the influence that specific cellular
mechanisms could have on SFHR efficiency, in order to increase
technique efficacy. Several experimental variables were investi-
gated such as SDF structure, cell cycle and DNA methylation of
both SDF and recombinant host genome.
Increased replacement efficiency will be useful for further ex vivo
SFHR gene therapy applications.
Results
Clones construction and eGFP genomic integration
In vitro mutagenesis was carried out on pCEP4 residue 210
located in the coding region of wt eGFP gene. The glutamine
(CAG) to stop codon (TAG) transition causes, at the same time, a
fluorescence switch off and a BtsI restriction site disruption
(Fig. 1A). Successively SV-40 immortalized MEF were transfected
with linearized either wild type (pCEP4/wt-eGFP) or mutated
(pCEP4/mut-eGFP) plasmids. Clonal dilution and hygromycin
selection were performed to obtain homogeneous transgenic cell
lines, stably integrating wild type or mutated copies of eGFP gene,
as demonstrated by sequencing (Fig. 1B) and FACS analyses
(Fig. 1C). For each clone pCEP4/eGFP copy number was
determined by Taqman qPCR (Fig. 1D). Genomic DNA and
cDNA amplification followed by BtsI enzymatic digestion
confirmed the presence of the inserted mutation in all mutated
clones (data not shown). Moreover FISH analysis on D1 clone
demonstrated the genomic integration of the pCEP4/mut-eGFP
vector (Fig. S1). Among four mutated cell clones, D1 was
employed for all the experiments because containing only one
copy of the transgene. D1 represented our assay system in which
different parameters were tested, in order to quantify the efficiency
of gene modification.
Transfection parameters setting
After optimization of transfection conditions (Fig. S2 and
Information S2), SDF concentration was tested: 1.7610
6 unsyn-
chronized cells were transfected with increasing amounts of SDF-
PCR-WT ranging from 5 mg( 3 610
6 SDF/cell) to 30 mg (18610
6
SDF/cell) (Fig. 2A). Targeted correction rates were measured by
flow cytometry 3 days after transfection. The best efficiency
(0.05%, *p=0.00002) was obtained using 12610
6 molecules of
SDF/cell (20 mg) (Fig. 2A and Fig. S3). This amount has been used
for all further transfections. Higher SDF concentrations (18610
6
SDF/cell) were also tested eliciting increased cell mortality (data
not shown).
We then evaluated three different experimental protocols for
SDFs synthesis, relating them to correction efficiency. Specifically
a SDF-PCR-WT fragment, 876 bp long, either double (ds) or
single stranded (ss), obtained by enzymatic amplification, and a
SDF-DIG-WT fragment, 752 bp long, obtained by digestion of
pCR-2.1 vector was used (Fig. 1A). Three days after transfection, a
correction frequency of 0.05% (*p=0.001) was detected by FACS
when ds-SDF-PCR-WT was used, resulting five-folds higher than
ds-SDF-DIG-WT (0.01%, p,0.07) (Fig. 2B and Fig. S4). The
repair frequency obtained using a control SDF (CTR), homolo-
gous to mutated eGFP sequence, was essentially identical to
background (about 0.00001%). Heat denatured ss-SDF-PCR-WT
fragment produced an efficiency of 0.01%, equivalent to that
obtained by SDF-DIG-WT (Fig. 2B, p=0.07).
If not differently stated, the SDF hereafter used in this work is
always double stranded.
Cell cycle, SDF methylation and modification efficiency
Manipulation of cell cycle progression by inducing DNA
damage has recently been shown to be one factor governing the
frequency of the targeted gene repair reaction [16].
To determine whether cell cycle phase might affect the
efficiency of gene repair, we evaluated gene targeting in cell
populations enriched in G0/G1, S, and G2/M phases. Cell
synchronization was previously optimized in order to obtain an
high cell cycle enrichment together with an high cell viability
(Fig. 3A, grey columns). Best synchronization conditions were
Figure 1. Experimental design for SDF and cell clone genera-
tion. A) SDF sequence is homologous to the entire wild type eGFP
coding sequence. SDF-PCR-WT, 876 bp long was generated by PCR
amplification with primer pair 1F/1R (Table 1). SDF-DIG-WT, 752 bp
long, was obtained by HindIII and XhoI digestion of pCR-2.1 vector. C/T
transition, responsible of fluorescence switching off, is showed. B)
Sequencing analysis showing wild type (WT; top panel) and mutated
(Mut; bottom panel) pCEP4-eGFP in C1 and D1 cell clones, respectively.
Arrows indicate the modified base (CRT). C) FACS density plot of C1
(WT; top) and D1 (Mut; bottom) respectively. D) pCEP4-eGFP copy
number determination for each cell clone.
doi:10.1371/journal.pone.0030851.g001
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after used to treat cells before transfecting 12610
6 molecules/cell
of SDF-PCR-WT (Fig. 3B and Fig. S5). Fluorescence was
quantified 72 hours after transfection to exactly determine
phase-specific gene repair frequencies. Compared to unsynchro-
nized cells (Fig. 2B and Fig. S4; 0.05%), G2/M synchronized cells
showed an increased correction efficiency to 0.5% (*p=0.0001
respect to CTR and +p=0.0001 respect to unsynchronized cells).
No significant differences in modification efficiencies were
detected comparing synchronized with unsynchronized cells in
G0/G1 (0.05%, p=0.001 respect to CTR and n.s. respect to
unsynchronized cells) or in S phase (0.07%, p=0.0008 respect to
control and n.s. respect to unsynchronized cells) (Fig. 3B and Fig.
S5). CTR column indicates synchronized cells transfected by SDF
homologous to mutated eGFP sequence.
To test the hypothesis about the influence of SDF methylation
on SFHR efficiency, differently methylated SDFs were produced in
vitro using SssI or Dam or both DNA-methyltransferases, and then
transfected into G2/M synchronized cells (Fig. 3C, Fig. S6 and
Fig. S7 and Information S2). The efficiency of SDF replacement
was up to 80% lower (Dam
+ methylation; 0.12%) than that
obtained transfecting SDF-PCR-WT (0.48%), where no methyl-
ation was present. A reduction of about 50% was observed when
SDF-DIG-WT, harboring prokaryotic methylation (Fig. S7), was
used (0.22% vs 0.48%; Fig. 3C and Fig. S6).
Cell sorting and molecular analysis
SDF-PCR-WT (12610
6 molecules/cell) was transfected into
G2/M synchronized cells and fluorescent events were sorted
(Fig. 4A), FACS reanalyzed (to check cell population purity) and
placed in culture for several passages (about 10). Molecular
analyses were performed on a sorted cell population to confirm
genomic modification and its persistence over time. RFLP analysis
was performed on a 986 bp amplicon using BtsI enzyme, whose
restriction site has been recovered as result of successful SDF
replacement. Primers design (RFLP F and RFLP R; Fig. 4B and
Table 1) allowed the amplification of both wild-type and mutant
eGFP sequence, avoiding randomly integrated or free SDFs.
Sorted positive D1 clone restriction pattern (Fig. 4C, lane 1) was
clearly comparable to parental C1 clone in which wt eGFP
sequence was present (Fig. 4C, lane 5). No restriction bands were
present in CTR (Fig. 4C, lane 2; in which a SDF homologous to
mutated eGFP sequence was transfected) and in sorted negative
non fluorescent cells (Fig. 4C, lane 3), indicating no correction.
Direct sequencing of the analytical amplicon demonstrated the
presence of wild type base (cytosine C) at position 210 of the
coding region in D1 sorted positive cells (Fig. 4D). Thymine (T),
belonging to the mutated gene, was present in D1 sorted negative
and D1 CTR DNA. No other base alteration was evidenced.
Allelic discrimination by Real Time PCR was also performed
confirming previous results (Fig. S8).
Southern blot analysis was performed to further assess genomic
modification (Fig. 5). D1 sorted positive and negative cells were
compared to control cells (D1 CTR) and to parental C1
fluorescent clone. SalI/BtsI digested genomic DNA was probed
to a 566 bp DNA fragment homologous to the SDF (Fig. 5A). As
expected, in SFHR-modified cells (Fig. 5B, lane 1) and in the C1
clone (Fig. 5B, lane 4) only the 1111 bp band was clearly
detectable, demonstrating BtsI site recovery in D1 sorted positive
cells. A higher band of 1705 bp was present in D1 non-fluorescent
(Fig. 5B, lane 2; negatively sorted) and in D1 CTR (Fig. 5B, lane 3;
transfected with SDF homologous to mutated eGFP sequence).
Genomic DNA methylation involvement in the
inactivation of eGFP expression
By culturing D1 fluorescent cells, a gradual loss of eGFP
expression was noticed (Fig. 6A). A similar trend was observed in
parental C1 (data not shown). Retro-mutation was excluded by
both RFLP and sequencing analyses, confirming the presence of
SDF-mediated C nucleotide, regardless to cell fluorescent
phenotype (data not shown). To assess DNA methylation
involvement in the eGFP expression, D1 SDF-modified cells were
resorted. eGFP sorted negative cells (but still carrying the
correction) were treated for 24 and 48 hours with 0.5 mMo f5 -
Aza-29-Deoxycytidine (5-Aza-dC). eGFP expression, monitored by
Real Time-PCR (Fig. 6B), showed more than a four-fold increase
after 24 hours (*p=0.002). The expression further doubled after
48 hours of treatment, when compared to untreated cells
(*p=0.002). Untreated cells usually showed a decreasing relative
eGFP expression according to fluorescence decrement (data not
shown). These results demonstrated that the percentage of SDF-
mediated modification in transfected cells was underestimated,
because of a methylation-mediated silencing of eGFP expression.
To investigate the correlation between the eGFP locus methylation
status and its time-dependent expression, studies by multiplex
HpaII/PCR and AciI/PCR analysis were performed using either
C1 parental or D1 SDF-corrected cells (Fig. 7). Three different
Figure 2. Amount and type of transfected SDF. A) Correction
efficiencies after transfecting different amounts of SDF-PCR-WT in D1
cells. Positive events are used to determine the overall modification
efficiency respect to D1 control cells transfected with a SDF
homologous to mutated eGFP sequence (CTR). B) Different kind of
SDFs were tested in D1 cells: double (ds-SDF-PCR-WT 12610
6 SDF/cell)
or single strand (ss-SDF-PCR-WT 12610
6 SDF/cell) PCR fragments and
fragment obtained by enzymatic digestion (ds-SDF-DIG-WT 12610
6
SDF/cell) were compared to cells transfected with SDF homologous to
mutated eGFP sequence (CTR). For representative FACS dot plots see
Fig. S3 and S4.
doi:10.1371/journal.pone.0030851.g002
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promoter, were analyzed (Fig. 7A, S9 and S10 and Information
S2). In Figures 7B and 7C the percentage of methylation obtained
from densitometric analyses of electrophoretic restriction pattern
of the three amplicons is reported (see also Fig. S9, S10). In both
C1 fluorescent and non fluorescent sorted populations, the d
amplicon (Fig. 7B) resulted the most methylated, either for HpaII
or AciI, while in the e amplicon neither HpaII nor AciI methylation
were evidenced. In the c amplicon the HpaII methylation was
lower than in d fragment, whereas the AciI methylation resulted
absent. Importantly always non-fluorescent cells showed the
highest levels of both HpaII and AciI methylation. In the parental
C1 clone there is a good correlation between eGFP inactivation
and both HpaII and AciI DNA methylation patterns. The same
analysis was carried out on SFHR-modified D1 cells. After sorting,
fluorescent cells were placed in culture and, as previously
observed, gradually lost fluorescence. A re-sorting of phenotipi-
cally heterogeneous corrected D1 cells allowed us to distinguish
between eGFP
+ and eGFP
2 cells. In fluorescent modified-D1 cells
(Fig. 7C) all the analyzed zones showed no or very low levels of
both HpaII or AciI methylation. On the contrary, non fluorescent
modified D1 cells showed considerable level of both HpaII and AciI
methylation, with the exception of the d zone that resulted devoid
of HpaII methylation. Also in D1 modified cells, methylation
resulted to be directly correlated with eGFP expression.
1,5-Isoquinolinediol drug treatment increase correction
efficiency
Finally, three drugs, potentially involved in SFHR mechanism,
were tested to verify their effect on correction efficiency.
Specifically KU55933, 1,5-Isoquinolinediol (1,5-ISQ) and a-
Amanitin were added to transfected cells, that are, respectively,
inhibitor of ATM kinase, PARP-1 and RNA polymerase II [23–
30]. No statistically significant variations in modification efficiency
were observed three days after transfection (Fig. 8, black bars)
respect to SDF-PCR-WT control sample, in which no drugs were
added.
To disclose methyl-hidden correction events, 5-Aza-dC was
added to all samples 24 hours after transfection (Fig. 8, white bars),
resulting in an overall increase of fluorescence, statistically
significant.
When 5-Aza-dC is added to 1,5-ISQ treated cells a statistically
significant increase in correction efficiency was obtained both
respect to cells untreated with 5-Aza-dC (Fig.8, 1,5 ISQ black bar,
Figure 3. Modification efficiencies obtained testing different concentrations of mimosine, thymidine, vinblastine and SDFs with
different superimposed methylation patterns on D1 cells. A) For each drug the concentration that gives the highest percentage of
synchronized cells and the lowest cell death (highlighted in grey) was selected. B) Correction efficiencies after transfection in different cell cycle
phases. A SDF homologous to mutated eGFP sequence was used as control (CTR). Gene modification efficiency was enhanced when cells are
synchronized in G2/M phase (*p=0.0001 respect to CTR and +p=0.0001 respect to unsynchronized cells, Fig. S5). C) Differently in vitro methylated
SDFs were tested to assess methylation involvement in gene modification efficiency. SDF-PCR-WT gave the highest efficiency of modification (*p
resulted to be significant when compared to all treatments; specifically p=0.002 respect to Dam+, p=0.01 respect to SssI+, p=0.008 respect to
Dam+/SssI+, and p=0.009 respect to SDF-DIG-WT). For representative FACS dot plots see Fig. S5 and S6.
doi:10.1371/journal.pone.0030851.g003
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bar, *p=0.003).
These data indicated PARP-1 as a potential SFHR-efficiency
modifier.
Discussion
During last years, gene repair approaches received increasing
attention because of their safety compared to traditional gene
therapy strategies, where additional copies of therapeutic genes are
delivered and expressed in transduced cells [31–34].
Gene repair strategies attempt to directly correct endogenous
genetic mutations in situ, maintaining gene regulation under
endogenous promoter control. Targeted gene conversion repre-
sents also a tool for functional genomics in order to define gene
function. Furthermore, it is particularly intriguing the possibility of
gene-targeting in stem cells, that is the primary aim in both
therapeutic application and functional genomics [35,36].
Issues associated with this technique are still numerous and
many steps involved in gene correction process are still unknown
[3,37]. Thus it is critical that gene repair becomes an efficient and
reproducible strategy before its application to clinical medicine.
In this study, we developed a reporter-based assay system useful
to optimize SFHR experimental procedure. A mammalian
immortalized cell line was created with a stably integrated eGFP
gene. After transfecting SDFs into these cells, FACS analysis
allowed to quantitatively assess gene correction efficiency,
considering each fluorescent cell as a single correction event.
Several parameters (potentially involved in the SFHR process)
were evaluated: SDFs preparation, concentration, methylation
and delivery; integrated eGFP gene methylation pattern after
correction and, more importantly, the influence of cell cycle in the
gene modification process.
Moreover three drugs were tested, whose targets could play a
key role in SFHR process.
Optimal SDF concentration was identified. Moreover fragment
synthesis by PCR amplification resulted to be preferable to that
obtained by plasmid restriction probably because of the methyl-
ation pattern. To confirm this aspect, in vitro methylated fragments
(Dam, SssI or both) were tested. The low correction efficiencies,
obtained using methylated SDFs, could arise from a still unknown
mechanism, possibly involving methyl-binding protein that could
inhibit their integration within genomic DNA.
Studies on oligonucleotide ssODNs and cell cycle indicated that
gene modification frequencies varied considerably between the
various cell cycle phases, in particular late S-phase was shown to
be the most amenable for gene repair [20], probably due to
increased activity of replication forks and to a more favorable
chromatin conformation. Transfecting SDFs into cells synchro-
nized in different cell cycle phases, we noticed that replacement
Figure 4. Molecular analyses of sorted D1 cells. A) Modification efficiency in D1 cells transfected with 12610
6 SDF-PCR-WT/cell. Positive cells
(0.5%) were sorted and soon after reanalyzed (right panel) to asses population purity (.99%). B) PCR/RFLP analysis design. C) Amplicon is generated
using RFLP primer pair. Cells transfected with mutated SDF represent our control (D1 CTR, lane 2). All amplification products were digested with BtsI,
except lane 4. Restriction patterns of Sorted positive D1 clone (lane 1) and of parental eGFP C1 cells (lane 5) were identical. No restriction bands were
present in D1 CTR (lane 2) and in sorted negative cells (lane 3). M is ladder 50 bp. D) Sequence analysis of D1 cells (sorted positive, sorted negative
and CTR). The site-specific T-to-C conversion was present only in sorted positive cells.
doi:10.1371/journal.pone.0030851.g004
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Correction takes place also in G0/G1 or S phase, even if with
lower efficiency. SDFs, differently from ssODNs [20], seem to
have a greater probability to access the target locus during G2/M
phase possibly because chromosomes, already replicated (tetra-
ploid status), are still organized in loosely packed fibers.
Southern Blotting analysis suggest that random integration (due
to Non-Homologous End Joining of the fragment) is low at best
[38], however the possibility that it can occur below the level of
detection of the analytical system cannot be dismissed. Regarding
genomic methylation, the quantitative levels of methylation of the
integrated eGFP locus appeared to be correlated with cell
replication, in both parental C1 clone (where wild type e GFP
locus is present) and in D1 corrected clone. It should be noted that
D1 corrected cells have been sorted twice: soon after transfection
(isolating corrected fluorescent from non-corrected non-fluores-
cent cells), and after in vitro fluorescence decrease (isolating in this
case two cell populations both corrected: fluorescent and silenced
non-fluorescent).
The methylation patterns is however different in C1 and in D1
resorted clones: the first appeared to be more prone to methylate
the 39 end of the SFHR target region (d amplicon), the second
preferentially underwent to methylation of regions upstream and
downstream the SFHR target region (c and e amplicon). It should
be taken into account that this effect may depend on the fact that
the correction of D1 clone was achieved by the integration of a
non methylated PCR product that can undergo to a slower
methylation dynamics during cell replication. However a change
in the methylation patterns may specifically arise as consequence
of the recombination event possibly recognized by cellular
machinery of defense from invading DNA; anyway this leads to
gene silencing and consequently to an underestimation of
correction events [39]. Even the hypothesis that the differences
in methylation patterns between C1 parental cell line and D1
corrected clone are due to the epigenetic background of the
genomic zone where the eGFP construct inserted cannot be ruled
out. These effects seem to be also site-specific, in fact HpaII and
AciI methylation patterns resulted qualitatively and quantitatively
different. These results indicate DNA methylation as an
experimental variable to be considered, because partially masking
the real efficiency of SDF-mediated correction.
In order to preserve the integrity of the genome, cells have
developed various pathways to sense and overcome DNA damage.
Environmental factors like radiations or toxins, as well as
spontaneous DNA lesions, trigger checkpoint activation and
consequent cell cycle arrest allowing DNA repair or leading to
apoptosis. Two key proteins are mainly involved in recognition of
DNA damage and signal transduction to p53: ATM and PARP-1.
PARP-1 participates mainly in base excision repair (BER),
whereas ATM mainly in homologous recombination (HR) [40–
41]. ATM is a protein kinase capable to arrest the cell cycle
following DNA damage, thus activating DNA double strand
breaks repair machinery [23–26] while PARP-1 participates in
signaling from DNA single strand lesions. Recently PARP-1 has
been linked to the regulation of chromatin structure and
transcription, DNA methylation and imprinting, insulator activity,
and chromosome organization, playing key roles in a number of
nuclear processes [27–29]. Moreover, it should be taken into
account that transcribed parts of the genome are more efficiently
repaired and DNA damage is removed faster from transcribed
Table 1. Sequence and characteristics of primers.
Name Sequence Annealing Amplicon Fragment
Mutagenesis f CCTACGGCGTGTAGTGCTTCAGC 55uC
Mutagenesis r GCTGAAGCACTACACGCCGTAGG
eGFP f CTGCTGCCCGACAACCA 60uC7 4 b p
eGFP r ATGTGATCGCGCTTCTCGTT
eGFP probe 6FAM-CCAGTCCGCCCTGAGCAAAG-TAMRA
ApoB f CACGTGGGCTCCAGCATT 60uC7 4 b p
ApoB r TCACCAGTCATTTCTGCCTTTG
ApoB probe VIC-CCAATGGTCGGGCACTGCTCAA-TAMRA
RFLP f CACTGCATTCTAGTTGTGGTTTGT 55uC 986 bp
RFLP r CACCAAAATCAACGGGACTT
1f ACTCATCAATGTATCTTATCAT 55uC 876 bp SDF-PCR-WT
1r AGGTCTATATAAGCAGAGCT
5f CGTAAGTTATGTAACGCGGAACTC 64uC 167 bp St3
5r GGCCATTGCATACGTTGTATC
6f GTAGGTCAGGGTGGTCACG 64uC 699 bp c
6r GTAACGCCAATAGGGACTTTCC
7f AACTTGTTTATTGCAGCTTATAATGG 64uC 383 bp d
7r AGATCCGCCACAACATCG
8f AAAACCTCTACAAATGTGGTATGG 64uC 503 bp e
8r CATAAAGGCAATGTTGTGTTGC
8f1 GGGGACCAAACACAAAGG 64uC 138 bp St4
8r CATAAAGGCAATGTTGTGTTGC
doi:10.1371/journal.pone.0030851.t001
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purpose we tested three drugs affecting different proteins that
could be potentially involved in the mechanism of SFHR: KU-
55933, a specific ATM kinase inhibitor, 1,5-Isoquinolinediol,
PARP-1 inhibitor, and a-Amanitin, able to block RNA polymer-
ase II and prevent transcription initiation and elongation. No
statistically significant differences were detected treating cells with
the above compounds. Only after 5-Aza-dC addition, cells showed
an overall increase in fluorescence significant in 1,5-Isoquinoline-
diol treated cells. This seems to suggest that, once the SDF is inside
the cells it doesn’t need high activity either of ATM (KU-55933),
possibly due to a lack or low levels of double strand breaks in the
genome, or of transcription dependent repair pathways (a-
Amanitin). The real SFHR-mediated correction efficiency seems
to be exactly quantified only after 5-Aza-dC addition, allowing
moreover to highlight the effect of 1,5-Isoquinolinediol on overall
correction.
The influence that PARP-1 inhibition has on SFHR-modifica-
tion efficacy could be explained by recent findings reporting how
PARP-1 inhibition leads to stalled replication fork with consequent
formation of DNA double strand breaks that are resolved by
homologous recombination through ATM activation [42]. We
believe more in a HR pathway involvement than NHEJ, because
our results indicated that SFHR is mainly favored in G2/M phase,
known to be a phase where this pathway is much more active than
in other cell cycle phases. On the other hand it was reported that
the inhibition of PARP-1 may increase the methylation of genomic
DNA [43,44]. This may be the reason why a significant increase of
fluorescence expression in cells treated with PARP-1 inhibitor, was
evident only after 5-Aza-29-Deoxycytidine addition.
Anyhow a more accessible hypomethylated chromatin may
enhance events otherwise not clearly visible. In this regard, a more
direct involvement of the PARP-1 repair pathway possibly limiting
the efficiency of SFHR may be also proposed; the inhibition of
PARP-1 might favor the SDF integration, particularly when the
chromatin switches to a hypomethylated open conformation
allowing the integration of those residual intracellular SDFs not
yet integrated.
Different SFHR-modification efficiencies have been reported
[7–17], suggesting that the protocol is highly dependent to several
Figure 5. Southern blot analysis. A) Probe design. A 566 bp probe
was used, recognizing a region of eGFP gene. Dashed box correspond
to pCEP4-eGFP locus integrated within genomic DNA. BtsI site recovery
highlight the correction of the eGFP gene. After SalI/BtsI genomic DNA
digestion, two different restriction pattern can be obtained, according
to the presence/absence of BtsI restriction site. B) Southern blot. A
1111 bp band was obtained only in cells in which BtsI site is present (D1
sorted positive and C1 clone).
doi:10.1371/journal.pone.0030851.g005
Figure 6. eGFP expression increased after 5-Aza-29-Deoxycyti-
dine treatment. A) Bright field (upper row) and fluorescent (bottom
row) images of D1 sorted corrected cells at different experimental time
(scale bar: 150 mm). B) eGFP expression, analyzed by Real Time PCR,
after 24 h and 48 h of treatment with 0.5 mM 5-Aza-29-Deoxycytidine
respect to untreated (0 h) (*p=0.002); untreated cells, at 24 h and 48 h,
usually showed a decreasing relative eGFP expression (data not shown).
doi:10.1371/journal.pone.0030851.g006
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correction efficiency seems to be crucial to improve the strategy.
The assessment and verification of sequence-specific modification
of genomic DNA is complicated by the fact that the genomic
targets to be modified generally involve endogenous genes that are
not readily amenable to enrichment strategies. Therefore a model
based on the use of reporter gene and/or selectable marker
becomes useful to assess both the overall frequency of targeted
DNA repair and to optimize modification protocols.
In this study several evidences about SFHR have been reported:
the demonstration of a heritable event of gene modification in a
cell clone by molecular analyses, the demonstration of phenotypic
reversion (due to genetic modification) by functional assays, and an
accurate calculation of gene correction frequency, avoiding
artifacts such as those related to PCR-based techniques [45] and
to the raising of genomic methylation patterns after correction.
Southern blot also demonstrated genomic modification SDF-
mediated of the eGFP locus. In addition, site-specific DNA
methylation was shown to be quantitatively correlated to the target
gene inactivation; these methylation patterns arose with cell
replication and appeared to be influenced by the recombination
event. Also the involvement of PARP-1-mediated repair system
and its interplay with chromatin structure were evidenced. If this
involvement is direct or indirect deserves further studies.
By this way additional insight into the comprehension of the
parameters mediating the efficacy and specificity of the genomic
replacement will be essential to the wider application of these
protocols as therapeutic agents.
Figure 7. HpaII and AciI methylation analyses of integrated eGFP in C1 and D1 clones. A) Experimental design showing the amplicon
regions and their length within eGFP locus integrated in genomic DNA. HpaII and AciI site are indicated. B) Densitometric analyses of parental C1
clone methylation pattern on eGFP
+ more positive, eGFP
+ less positive and eGFP
2 cells (see also Fig. S9B and Fig. S10B). ANOVA test gave a statistical
significance of p,0.001 and p,0.005 respectively for HpaII and AciI panels. C) Densitometric analysis of methylation pattern of D1 SFHR-modified
clone on both fluorescent and non fluorescent cells (see also Fig. S9C and S10C). ANOVA test gave a statistical significance of p,0.001 for both
panels.
doi:10.1371/journal.pone.0030851.g007
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Ethic Statement
No ethic statement was required because the study was only
performed in vitro on an immortalized cell line. Mouse embryonic
fibroblast were derived in strict accordance with the recommen-
dations in the Guide for the Care and Use of Laboratory Animals
of the National Institutes of Health.
Cells and culture conditions
Mouse embryonic fibroblasts (MEF) were kindly provided and
derived by Dr. Emanuela Bruscia from Yale University (unpub-
lished data) from 13 d.p.c. pregnant female, as described [46].
Isolated cells were cultured in DMEM (Euroclone, Milan, Italy)
with 10% FBS (Euroclone, Milan, Italy), 1% L-glutammine
(Euroclone, Milan, Italy) and 1% of Penicillin/Streptomycin
(Euroclone, Milan, Italy), at 37uC under 5% CO2. For cell
transformation, SV-40 infection was performed on 1610
5 MEF in
4 ml of medium containing 4 mg/ml of polybrene. After the
infection, cells were cultured in DMEM, 10% FBS, 1% Non
Essential Aminoacids (Invitrogen, CA, USA), 0.01 mM of 2-Beta-
Mercaptoethanol (Invitrogen, CA USA), 20 mM Hepes (Euro-
clone, Milan, Italy), 2 mM L-glutammine (Euroclone, Milan, Italy)
and incubated at 37uC under 5% CO2. 48 hours after infection
cells have been trypsinized and plated with a density of 100 cells/
well in a 96-well plate adding 400 mg of G418 (Euroclone, Milan,
Italy) for cell selection.
Construction of the stably integrated mutant and wild-
type eGFP cell lines
The wild type eGFP gene was obtained from the pEGFP-N1
vector (Clonetech Lab. Inc., USA) by XhoI and HindIII restriction
(New England Biolabs, Ipswich, MA, USA), and cloned in vector
pCR-2.1 (Invitrogen, CA, USA). The wild type sequence of the
gene was mutated by QuikChangeH Site-Directed Mutagenesis
Kit (Agilent Technologies Inc, Santa Clara, CA, USA) using two
specific mutagenesis primers (Table 1). The eGFP gene was
mutated at codon 70 (CAG.TAG) creating a stop codon and, at
the same time, eliminating a BtsI restriction site (in order to be able
to screen the corrected clones). The mutated and the wild-type
gene were extracted from pCR-2.1 vector by restriction with XhoI
and HindIII and cloned inside the pCEP4 vector (Invitrogen, CA,
USA), between pCMV promoter and SV40-pA, using the same
restriction enzymes. To create stable cell clones, 3 mg of each SgrAI
linearized plasmid were added to 1.7610
6cells and once
transfected cells were plated in 75 cm
2 flask in fresh medium
containing 200 mg/ml of hygromycin (Sigma-Aldrich, Milan,
Italy) for stable vector integration selection. The cells were
cultured for two weeks in selective medium using 500 mg/ml of
hygromycin. After selection, several single cell clones were isolated
by serial dilution in 96 well plate and screened by PCR and FISH
analyses to check genomic plasmid integration. Among selected
clones, D1 was chosen for our experiments, as integrating mut-
eGFP gene sequence, and C1 clone as positive control, because
containing wt-eGFP gene. Metaphase chromosome preparations
for fluorescent in situ hybridization (FISH) were made from D1
and C1 clones. pCEP4was used as probe and slides were processed
as previously described [47].
Plasmid standard curve and copy number determination
To create plasmid standard curve we have followed Applied
Biosystems online protocol. For each point of the ten-fold dilution
standard curve, the mass of plasmid DNA containing the copies of
interest, ranging from 300.000 to 30 copies, has been calculated.
qPCR was conducted with 100 ng of DNA in triplicate in a 25 ml
reaction using the TaqMan PCR Universal Master Mix and the
Applied Biosystems 7500 Fast Real-Time PCR System (Applied
Biosystems, Foster City, CA, USA). Primers and probe sequences
for eGFP and ApoB (Table 1) were designed using the Primer
Express 2.0 software (Applied Biosystems, Foster City, CA, USA).
ApoB (endogenous control) was used, in separate reactions, to
verify the template DNA concentration and integrity. The final
concentration of eGFP/ApoB primers was 400 nM each, and the
probe was 150 nM. Reactions followed standard ABI cycling
conditions. The copy number of eGFP transgene was calculated as
described [48].
eGFP SDF design, production and methylation
A 876 bp dsDNA SDF homologous to eGFP wild type sequence
(named SDF-PCR-WT) was obtained by amplification of the
region cloned in pCR-2.1 vector (Invitrogen, CA, USA), using 1f
and 1r primers (Fig. 1A, Table 1). The PCR product was purified
from 1% agarose gel by QIAquick Gel Extracion Kit (Qiagen,
Manchester, U. K). Another kind of ds-DNA SDF (752 bp),
homologous to eGFP wild type sequence, was obtained by HindIII
and XhoI restriction of the pCR-2.1 vector (named SDF-DIG-
WT). The sequence of the SDFs was checked by DNA sequencing.
The ss-SDF-PCR-SDF was obtained by heat denaturation,
incubating 10 min at 100uC and soon after placed on ice. All
the fragments were dosed by spectrophotometer (ND-1000,
Nanodrop, USA). For in vitro methylation of SDFs, SDF-PCR-
WT was used as target. For Dam and SssI methylation, 1 mgo f
SDF-PCR-WT was incubated with 2 units of methyltransferase
(New England Biolabs, Ipswich, MA, USA) in a final reaction
volume of 20 ml. To create a Dam/SssI methylated fragment, we
performed a second SssI methylation step on previously Dam
Figure 8. Relative modification efficiency in D1 cells transfect-
ed with SDF-PCR-WT and treated with a-Amanitin, 1,5-
Isoquinolinediol and KU-55933. Transfected samples were ana-
lyzed three days after transfection (3 days; black columns) or in parallel
treated 24 hours after transfection with 0.5 mM of 5-Aza-dC for 48 hours
(1 day+2 days 5-Aza-dC; white columns). No statistically significant
differences were observed at 3 days (black bars) respect to untreated
cells (SDF-PCR-WT). Demethylating effect of 5-Aza-dC increased eGFP
detection in all samples (white columns) in a statistically significant
manner (D p=0.003; +p=0.01;N p=0.0007). 5-Aza-dC addition also
disclosed the effect of 1,5-Isoquinolinediol on SDF-mediated correction
in a statically significant manner respect either to cells not treated with
5-Aza-dC (**p=0.0002) and to the cells transfected with SDF-PCR-WT in
which no drug was added (*p=0.003). Dashed lines refers to
modification efficiency observed in cells without addition of any drug
but treated by 5-Aza-dC. Results are from mean values of three
independent experiments and are reported as relative modification
efficiencies in respect to control without drugs (SDF-PCR-WT).
doi:10.1371/journal.pone.0030851.g008
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incubating overnight treated samples with methylation-sensitive
restriction endonucleases followed by PCR amplification (Infor-
mation S1 and Table 1).
Cell synchronization
To systematically investigate SFHR-mediated gene repair at
various phases of the cell cycle, different concentrations of
mimosine, thymidine and vinblastine were tested to synchronize
cells in G0/G1, S or G2/M phase, respectively. For the mimosine
(Sigma-Aldrich, Milan, Italy) cells were grown for 12 hours at a
concentration ranging from 250 mM to 750 mM. For the
thymidine (Sigma-Aldrich, Milan, Italy) cells were gown for
15 hours at a concentration ranging from 0.5 mM to 4 mM.
Synchronization in G2/M phase was obtained growing cells for
14 hours at a concentration ranging from 25 nM to 200 nM of
vinblastine (Sigma-Aldrich, Milan, Italy). Once 60% of confluence
was reached, cells were treated, washed in PBS, fixed in 70%
ethanol, stained with 0.05 mg/ml propidium iodide and then
analyzed by FACS-Calibur Flow Cytometer (Becton Dickinson) to
determine DNA content. Sync-Wizard Model was used to model
the cell cycle. Before any SDFs transfection, for cell cycle phase
synchronization, cells were plated at a density of 7610
5 in a
150 mm dish, incubated with mimosine for 12 h, or thymidine for
16 h or vinblastine for 14 h.
Cell transfection and FACS analysis
Electroporation was carried out using the Amaxa Nucleofection
System (Lonza, Cologne, Germany). Appropriate Nucleofection
program was evaluated in order to have an optimal transfection
efficiency and cell viability. We tested two different electroporation
programs A-23 and T-20 and two different transfection solutions
MEF-1 and MEF-2 using a 21 bp fluorescent oligonucleotide. The
combination of program T-20 and solution MEF-2 was chosen
(Information S2 and Fig. S2). 12610
6 SDFs/cell were added to
1.7610
6 synchronized D1 clone cells and suspended in 100 mLo f
supplemented Nucleofection Buffer MEF-2. Transfection efficien-
cy based on a pMax-GFP (Lonza Cologne, Germany) reporter
plasmid was ,75%. Each time a negative control was used (a
mutated 876 bp SDF obtained by PCR). Three days after
transfection, cells were FACS analyzed using nucleic acid dye
Topro-3 (0.1 mM; Invitrogen, CA, USA) to exclude dead cells.
Data from 300.000 live cells were analyzed by the BD-ARIA-
DIVA software, to obtain the percentage of eGFP positive cells.
To gate eGFP positive cells, parental C1 clone was used. Every
experiment was performed in triplicate; every experimental
condition was tested in 2 to 3 independent experiments (overall
from 6 to 9 independent experimental replicated data).
KU-55933, 1,5-Isoquinolinediol, a-Amanitin and 5-Aza-29-
Deoxycytidine treatments
Cells were treated by three different inhibitors of specific
proteins. KU-55933 (Tocris, Bristol, U.K.), a potent, selective and
competitive ATM kinase inhibitor, was used at 10 mM one hour
prior transfection. 1,5-Isoquinolinediol (Sigma- Aldrich, Milan,
Italy), an inhibitor of Poly-(ADP-ribose) synthetase-1, was used
soon after transfection at 0.622 mM for 24 hours.
a-Amanitin (Sigma-Aldrich, Milan, Italy), an inhibitor of
eukaryotic RNA polymerase II and III, was used 24 h after
transfection at 1 mM for 24 hours. Treated cells, previously
synchronized, were then transfected, as described above. To verify
a relationship between methylation status of eGFP locus and time-
dependent eGFP expression one day after transfection, cells were
incubated with 0.5 mM 5-Aza-29-Deoxycytidine (Sigma-Aldrich,
Milan, Italy) for 48 h and then FACS analyzed as described above.
Every experiment was performed in triplicate; every experimental
condition was tested in 2 to 3 independent experiments (overall
from 6 to 9 independent experimental replicated data).
Southern blot hybridization, sequencing, and restriction
analysis
For Southern blot analyses, genomic DNA was isolated from D1
and C1 clones by Flexigene kit (Qiagen, Manchester, U.K.),
according to protocol. The genomic DNA was digested (10 mg) by
SalI and BtsI, both cutting inside the pCEP4 vector and analyzed
by electrophoresis in 0.8% agarose gel. The DNA was transferred
to a nylon Hybond N
+ membrane (Amersham-Phamacia Biotech,
Piscataway,NJ, USA) and hybridized overnight at 65uC with an
32P-labeled probe. Probe was generated by PCR from wt-eGFP
sequence using the same primer pair for SDF generation.
Amplicon was then digested at 37uC with BtsI enzyme and the
566 bp band was gel purified and used as probe. Successful site-
specific T to C conversion in the eGFP reporter gene was
evidenced by: i) sequence analysis; ii) restriction enzyme analysis
and iii) allelic discrimination (Information S1). For sequencing and
restriction analyses, genomic DNA was isolated from transfected,
untransfected and sorted corrected cells, as described above, and
eGFP locus amplified by using RFLP-f and RFLP-r primers
(Fig. 4B, Table 1) located outside the SDF region. The PCR
product (986 bp) was resolved by 1% agarose gel electrophoresis,
purified using QIAquick gel extraction kit (Qiagen, Manchester,
U.K.) and resuspended in demineralized water. Gel purified
amplicons were directly sequenced by cycle sequencing with a
BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosys-
tems, Foster City, CA, USA) using the same primer pair as for
amplification. The sequencing reactions were carried out in a
10 ml final volume according to manufacture protocol. Electro-
phoretic separation was carried out on an ABI Prism 310 Genetic
Analyzer (Applied Biosystems, Foster City, CA, USA). To asses
gene modification, a BtsI restriction digestion at 55uC was carried
on gel purified amplicons. Products were analyzed on a 2%
agarose gel.
RNA analysis of eGFP gene
C1 and D1 fluorescent cells were plated after sorting in a
100 mm plate 24 h prior to 0.5 mM 5-Aza-29-Deoxycytidine
(Sigma-Aldrich, Milan, Italy) treatment and incubated for 48 h.
After treatment, cells were analyzed for eGFP expression. Total
RNA was extracted according to Trizol protocol (Invitrogen, CA,
USA) and 1.5 mg of RNA were reverse transcribed to cDNA
according High-Capacity cDNA Archive kit protocol (Applied
Biosystems, Foster City, CA). Real time RT-PCR was performed
using a 7500 Fast Real-Time PCR System (Applied Biosystems,
Foster City, CA, USA) using the same primers for copy number
determination (Table 1). A commercially available endogenous
gene, Glyceraldehyde 3-phosphate dehydrogenase gene (GAPDH:
Mm99999915g1 Applied Biosystems) was used as reference for the
TaqMan assay. A comparative Ct method was used to quantify
relative gene expression. All PCR reactions were performed in
triplicate.
DNA methylation analysis
In order to characterize the relationship between methylation
status of eGFP locus and time-dependent eGFP expression, studies
by multiplex HpaII/PCR or AciI/PCR were performed on
genomic DNA of C1 and D1 modified clones, treated by HpaII
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England Biolabs, Ipswich, MA, USA). The methylation status of
different sites of the locus were analyzed by the selection of 3
regions: the upstream/SFHR target region (indicated as c
amplicon, Fig. 7A), the SFHR target/downstream region
(indicated as d amplicon; Fig. 7A) and the downstream region
(indicated as e amplicon; Fig. 7A). Two regions which possesses no
HpaII or AciI recognition sites, were used as internal standards for
HpaII/PCR and AciI/PCR (indicated respectively as St3 and St4
amplicon, Fig. 7A). Primer pairs were designed (Table 1) with at
least one primer located outside the SFHR targeted region
avoiding the amplification of non integrated SDF. 300 ng of
genomic DNA were digested at 37uC with 3 units of each enzyme
for 12 hours in a final volume of 20 ml. Only after the treatment
with methylation-sensitive restriction endonucleases, that cut the
target genomic DNA only if unmethylated, every single region was
amplified together with the internal standard in a multiplex
touchdown PCR. The touchdown PCR cycle was performed as
follow using a PTC100 Thermal Cycler (Bio- Rad): 29 of at 92uC,
40 cycles (450 at 94uC, 19300 at 64uC 20.2uC per cycle, and 49 at
72uC) and a final extension of 79 at 72uC. Gel electrophoresis run
was scanned by a CCD camera (VisiDoc-It, UVP) and acquired
on the VisionWorks LS software version 6.7.3 (UVP) for
densitometry. For a semi-quantitative evaluation of methylation
patterns of integrated eGFP construct, each target amplicon was
normalized for the corresponding control amplicon. The final
result is the percentage of methylation of the examined region
respect to corresponding uncut controls. All PCR reactions ad
densitometric analyses were performed at least in triplicate.
Statistical analysis
All data were compared by using the two-tailed, paired
Student’s t test analysis. Methylation densitometry data were
analyzed using analysis of variance (ANOVA). A p,0.05 was
considered statistically significant.
Supporting Information
Figure S1 Fluorescent in situ hybridization (FISH) on
D1 clone. The FISH analysis shows chromosomal localization of
the transgene. Arrows indicate the hybridization signals.
(TIF)
Figure S2 Optimization of nucleofection protocol by
FACS analysis after transfecting a 21 bp fluorescent
oligonucleotide. A) A representative density plot in which R1
identifies the viable D1 cell population. Dead cells were excluded
by propidium iodide staining. Histograms of R1-gated D1 cells are
shown. In the first row cells transfected by A-23 and T-20
programs are analyzed immediately after oligonucleotide trans-
fection (T=0 h). In the second row the same analysis was
performed 24 hours after transfection (T=24 h). Control (Ctr)
was transfected with a non fluorescent oligonucleotide. Fluores-
cence intensity was measured on the X-axis at 530630 nm
wavelength. The Mean Fluorescence Intensity (MFI) values
showed in the histograms suggested a transfection efficiency
similar for A-23 and T-20 programs at T=0 h. A decrease of
fluorescence was detected after 24 hours in A-23 transfected cells
respect to T-20 ones. B) Comparison of viability and transfection
efficiency testing T-20 and A-23 programs with two distinct
transfection solutions (MEF-1 and MEF-2). Combination of T-20
program and MEF-2 solution gave the highest transfection
efficiency together with low cell death.
(TIF)
Figure S3 Representative dot plots of D1 modification
efficiencies obtained testing different amount of SDF. A
SDF homologous to mutated eGFP sequence was used as control
(CTR). See Fig. 2A for overall results.
(TIF)
Figure S4 Representative dot plots of D1 modification
efficiencies obtained testing SDFs synthesized with
different experimental protocols.. A SDF homologous to
mutated eGFP sequence was used as control (CTR). See Fig. 2B
for overall results.
(TIF)
Figure S5 Representative dot plots of D1 modification
efficiencies after cell cycle synchronization. A SDF
homologous to mutated eGFP sequence was used as control
(CTR). See Fig. 3B for overall results.
(TIF)
Figure S6 Representative dot plots of D1 modification
efficiencies obtained testing several differently methyl-
ated SDFs. See Fig. 3C for overall results.
(TIF)
Figure S7 Analysis of methylation patterns of SDF-PCR-
WT treated with DNA-methyltransferases and of SDF-
DIG-WT. A) Analysis design. B) SDF-PCR-WT and SDF-DIG-
WT were treated by methylation sensitive restriction enzymes for
HpaII, Dcm or Dam methylation and used as target for following
amplification (central panels). Untreated samples, or samples
treated with heat inactivated restriction enzymes (left panels)
resulted to be uncut. Samples cut with methylation insensitive
isoschizomers (right panels: MspI, BstNI, Sau3AI) are shown as
controls. In all panels the lower band is the internal control of
amplification (amplicon from a zone without recognition sites for
restriction enzymes) always amplified, while the upper band is the
amplicon from the target sequence (see Fig. S7A for the
description of zones). The recognition sequence of each restriction
enzyme is reported on the right; the nucleotide that, if methylated,
prevents the cut by the sensitive restriction enzyme is underlined.
In every lane M a GeneRuler
TM 50 bp DNA Ladder is shown.
For HpaII and Dcm methylations target samples are repeated in the
same order, as follows: lanes 1 and 2 SDF-DIG-WT; lane 3, SDF-
PCR-WT; lane 4, pCR 2.1 plasmid; lane 5, negative control (with
water instead of DNA). For Dam methylation: lane 1, SDF-PCR-
WT; lane 2, pCR2.1 plasmid; lane 3 negative control. C)
Amplicons obtained from PCR-amplified (primers 1F/1R) SDF
in vitro methylated by Dam methyltransferase and MboI treated
(lane 1), methylated by SssI methyltransferase and HpaII treated
(lane 3) as well as methylated by both Dam and SssI and treated by
both MboI and HpaII (lane 5) are shown. Respective negative
controls, using unmethylated SDF as target (lanes 2, 4, 6) are
shown. Lanes M represents GeneRuler
TM 50 bp DNA Ladder.
The methylating treatment resulted effective, as superimposed
methylation pattern protect SDF from digestion. These methyl-
ated SDF are those used to test the effect of SDF methylation on
correction efficiency.
(TIF)
Figure S8 Allelic discrimination plot. Red and blue dots
represent wild-type (D1 sorted positive and parental C1 clone) and
mutated (D1-CTR) genotype, respectively.
(TIF)
Figure S9 CpG Methylation analysis of HpaII sites in C1
and D1 clones. A) Experimental design. For both B and C
panels the treatment of genomic DNA with active or non active
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zone (c, d, e amplicons) while the lower band is the control
amplicon (St3); B) eGFP negative (lanes 1–3), more positive (lanes
4–6), less positive (lanes 7–9) C1 parental cells; M: 50 bp marker.
PCR blanks corresponds to negative controls (no DNA; lanes 10
and 11). C) D1 eGFP negative (lanes 1–3), and positive (lanes 4–6)
cells; M: 50 bp marker. PCR blanks corresponds to negative
controls (no DNA; lanes 7 and 8).
(TIF)
Figure S10 CpG Methylation analysis of AciI sites in C1
and D1 clones. A) Experimental design. For both B and C
panels the treatment of genomic DNA with active or non active Aci
I is indicated; in each panel, the upper band is the analyzed zone
(c, d, e amplicons) while the lower band is the control amplicon
(St4); B) eGFP negative (lanes 1–3), more positive (lanes 4–6), less
positive (lanes 7–9) C1 cells; M: 50 bp marker. PCR blanks
corresponds to negative controls (no DNA; lanes 10 and 11). C) D1
eGFP negative (lanes 1–3), and positive (lanes 4–6) cells; M: 50 bp
marker. PCR blanks corresponds to negative controls (no DNA;
lane 7 and 8).
(TIF)
Information S1 Supporting Materials and Methods.
(DOC)
Information S2 Supporting Results.
(DOC)
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